Shopping Cart 0
Cart Subtotal
USD 0

SK Biopharmaceuticals Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

SK Biopharmaceuticals Co Ltd (SK Biopharmaceuticals), a subsidiary of SK Holdings Co Ltd is a researcher and developer of drugs. The company develops and markets drugs for the treatment of central nervous system. It provides plumiaz, SKL-N05 and JZP-110; YKP3089, relenopride, SKL-PD, SKL-A4R, SKL-PSY and FZ-016; SKL-ADHD and carisbamate drugs, among others. SK Biopharmaceuticals offers research and development; biological studies, preclinical studies, lead compound development and phase development services. The company provides development of next-generation drugs that maintains efficacy and minimizes side-effects and toxicity by harnessing life science technologies in new drug and development programs. It has developed drug candidates in the area of CNS such as epilepsy and GI with chronic constipation and constipation dominant irritable bowel syndrome. SK Biopharmaceuticals is headquartered in Seongnam, South Korea.

SK Biopharmaceuticals Co Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

SK Biopharmaceuticals Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

SK Biopharma Forms Joint Venture with Glycyx Therapeutics 11

SK Biopharma And AriBio Enter Into Co-Development Agreement For SKL-G 12

SK Biopharma Enters Into Co-Development Agreement With SK Chemicals For YKP-10811 13

SK Biopharma Enters Into Collaboration Agreement With PKU International HealthCare And Shanghai Medicilon 14

Acquisition 15

SK Holdings Acquires SK Biotech from SK Biopharma 15

SK Biopharmaceuticals Co Ltd-Key Competitors 16

SK Biopharmaceuticals Co Ltd-Key Employees 17

SK Biopharmaceuticals Co Ltd-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Recent Developments 19

Product News 19

05/24/2017: Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS 19

Clinical Trials 20

Jun 06, 2017: Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy 20

Jun 06, 2017: Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea 22

May 24, 2017: Jazz Pharmaceuticals to Present Phase 3 Data on JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy and with Obstructive Sleep Apnea, During 31st Annual SLEEP Meeting 24

Apr 26, 2017: Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness 26

Mar 20, 2017: Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea 28

Feb 08, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinson's Disease 30

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31


List Of Figure

List of Figures

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

SK Biopharmaceuticals Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

SK Biopharmaceuticals Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

SK Biopharmaceuticals Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

SK Biopharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

SK Biopharma Forms Joint Venture with Glycyx Therapeutics 11

SK Biopharma And AriBio Enter Into Co-Development Agreement For SKL-G 12

SK Biopharma Enters Into Co-Development Agreement With SK Chemicals For YKP-10811 13

SK Biopharma Enters Into Collaboration Agreement With PKU International HealthCare And Shanghai Medicilon 14

SK Holdings Acquires SK Biotech from SK Biopharma 15

SK Biopharmaceuticals Co Ltd, Key Competitors 16

SK Biopharmaceuticals Co Ltd, Key Employees 17

SK Biopharmaceuticals Co Ltd, Subsidiaries 18

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

SK Biopharmaceuticals Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.